INTRODUCTION AND OBJECTIVES: Accurate estimation of long-term risk of cancer-specific [CSM] and other-cause mortality [OCM] is of utmost importance for clinical management of patients diagnosed with kidney cancer. The aim of the study is to assess longterm mortality rates of a contemporary cohort of patients surgically treated for non-metastatic kidney cancer.
INTRODUCTION AND OBJECTIVES: Accurate estimation of long-term risk of cancer-specific [CSM] and other-cause mortality [OCM] is of utmost importance for clinical management of patients diagnosed with kidney cancer. The aim of the study is to assess longterm mortality rates of a contemporary cohort of patients surgically treated for non-metastatic kidney cancer.
METHODS: 1,704 patients with non-metastatic kidney cancer treated with either radical or partial nephrectomy between 1987 and 2015 in a prospectively collected institutional database were assessed. Outcomes of the study were the 10-year rates of CSM and OCM. A multivariable competing risk regression model was fitted to predict CSM and OCM. RESULTS: At a median follow-up of 72 months, 10-year rates of CSM and OCM were 11 and 14%, respectively. At competing risk regression analysis, age, platelets, cT and cN resulted associated with higher risk of CSM (all p<0.05). Conversely, female gender and year of diagnosis were associated with lower risk of CSM (all p<0.05). Moreover, age, CCI and tumour size resulted associated with higher risk of OCM (all p<0.05). Conversely, female gender and year of diagnosis were associated with lower risk of OCM (all p<0.05). After stratification according to age and cT (Figure 1 ), the 10-year CSM and OCM rates resulted 3.4 and 5% in group A; 8 and 24% in group B; 22 and 7.7% in group C and 31 and 24% in group D, respectively.
CONCLUSIONS: The relative impact on CSM and OCM in patients treated with surgery for kidney cancer is extremely heterogeneous according to host and cancer characteristics. The 10-years rates of CSM and OCM resulted 3.4 and 5% in younger patients with cT1 and 31 and 24% in older patients with cT2 or higher stage. These figures can aid clinical decision making providing a precise long-term mortality risk estimation. INTRODUCTION AND OBJECTIVES: Predictive models for recurrence in non-metastatic renal cell carcinoma (RCC) have been developed from general populations of RCC patients, including very few high risk patients. According, these models may not be ideal to stratify high risk patients for enrollment in adjuvant clinical trials such as patients with venous tumor thrombus. The purpose of this study was to compare predictive accuracy for a nomogram developed from nonmetastatic RCC patients with venous tumor thrombus with 3 existing prognostic models for RCC recurrence following surgery.
Source of
METHODS: A nomogram was developed from independent predictors after multivariable modeling of common clinical and pathologic variables. Receiver operator characteristic (ROC) curves were constructed to compare predictive accuracy of the nomogram with the University of California-Los Angeles Integrated Staging System(UISS), Stage Size Grade Necrosis (SSIGN) and Sorbellini models.
RESULTS: A total of 669 consecutive non-metastatic RCC patients with tumor thrombus were treated surgically from 2000-2014 at 6 institutions. Variables independently associated with RCC recurrence were increased tumor diameter per centimeter, body mass index per point, preoperative hemoglobin < lower limit of normal, IVC thrombus level above hepatic vein, perinephric fat invasion, and non-clear cell histology. Estimated overall 5-year RFS was 49%. A nomogram was developed using weighted variables in a development cohort (n¼465) and validated in a separate cohort (n¼204). The AUC for the thrombus nomogram was 0.738, which was significantly higher than AUC for the Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e735
Sorbellini model (0.623), UISS model (0.615) and SSIGN model (0.584). CONCLUSIONS: A nomogram developed specifically for nonmetastatic RCC patients with venous tumor thrombus has significantly greater predictive accuracy than general prognostic models in this high risk population. 

INTRODUCTION AND OBJECTIVES:
To date no studies assessed whether Charlson Comorbidy Index (CCI), American Society of Anesthesiologists score (ASA) and Eastern Cooperative Oncology Group performance status (ECOG) have the same ability to predict postoperative mortality in renal cell carcinoma (RCC) patients who undergo radical (RN) or partial nephrectomy (PN). The aim of the study was to assess the predictive ability of these indeces on other cause mortality (OCM) in patients treated with surgery for kidney cancer.
METHODS: We identified 2,648 T1-T4 patients treated with RN or PN for RCC between 1987 and 2014 at a single centre. Patients with distant metastases at diagnosis, with multiple lesions and with Von Hippel Lindau were excluded. Four multivariable Cox regression analyses (MVA) were performed to assess OCM predictors. Predictors included in Model 1 were age at surgery and gender (basic model). Predictors in Model 2, 3 and 4 were the same included into Model 1 plus CCI, ASA and ECOG, respectively. The discrimination of the accuracy of each model was quantified using the receiver operating characteristic-derived area under the curve with a time frame at 3-year. Decision curve analyses were performed to evaluate and compare the netbenefit associated with the use of the 3 indeces relative to the basic model.
RESULTS: 249 patients (9.4%) died of other causes. Overall, 82 (3.1%) patients died within 3 years after surgery. The median follow-up in patients who survived was 63 months . At MVA of Model 1, age (HR 1.1) and gender (HR 1.5) were independent predictors of OCM (all p0.004). At MVA of Model 2, 3 and 4, age and gender remained independent predictors of OCM (all p0.04). Furthermore, at MVA of model 2, 3 and 4 CCI (HR 1.3), ASA (HR 1.09) and ECOG (HR 1.9) reached the independent predictor status (all p<0.001). The accuracy of Model 1, 2, 3 and 4 were 74.5 vs 77.6 vs 76.3 vs 76.3. After decision curve analyses, there was no superior net-benefit of one model relative to the others.
CONCLUSIONS: We provided evidence that the difference in accuracy between the CCI, ASA and ECOG is clinically negligible. Interestingly, the increase in accuracy relative to the basic model of all three index is limited and there is no superior net-benefit of any of the examined indeces relative to the basic model. These findings suggest that there is an impending need of a disease-specific index to predict OCM in RCC patients submitted to surgery. At the moment, clinicians may use any of these indeces for RCC patients counselling to predict postoperative mortality after surgery. INTRODUCTION AND OBJECTIVES: Many previous reports have shown an increased risk of cancer recurrence in oncological patients receiving blood transfusions at surgery. In renal cell carcinoma (RCC), it has been postulated that blood transfusion might impact the immunosuppressive response with a subsequent decreased host-tumor surveillance. We aimed to evaluate if intraoperative blood transfusion (IBT) may be associated with cancer specific mortality (CSM) and overall mortality (OM) in RCC candidates to surgical treatment.
Source of
METHODS: We evaluated 2,528 consecutive patients diagnosed with RCC and treated with partial or radical nephrectomy between 1987 and 2011. IBT was defined as transfusion of allogenic red blood cells during surgery. Univariable and multivariable Cox proportional hazards regression analyses were used to predict CSM and OM. Covariates included age at surgery, gender, pathological T stage, pathological N stage, pathological grade, lymph vascular invasion, tumor size, Charlson Comorbidity Index (CCI), year of surgery, symptoms at the presentation and tumor necrosis. Preoperative hemoglobin and bleeding were also included in a second model to test the independent effect of IBT on the outcomes of interest.
RESULTS: Overall, 784 patients out of 2,528 (31%) received IBT. In those patients, the median number of units transfused was 3 (range 1-7). Patients receiving IBT were significantly older (median age 61 vs. 64, p<0.001), with higher CCI (median CCI 5% vs. 8%, p<0.001), more symptomatic (35% vs 50%, p<0.001) and with more advanced pathological characteristics, such as high grade (Fuhrman 3-4: 25% vs. 43%, p<0.001), tumor stage (pT3-4 17% vs. 45%, p<0.001) and lymph node invasion (pN1: 4 % vs. 14%, p<0.001). Median follow-up was 72 months (IQR 10-90). Receipt of IBT was associated with CSM (HR 3.15 95% CI: 2.54-3.92, p<0.001) and OM (HR 2.40 95% CI: 2.07-2.78, p<0.001). At multivariate analyses, IBT was associated with higher risk of OM (Hazard ratio [HR] 1.09; [CI] 1.006-1.192; p<0.05). Among patients who received IBT, an increasing number of units transfused was independently associated with increased OM (HR 1.14 [CI] 1.05-1.21; p< 0.05).
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